PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
AHA 18

ODYSSEY OUTCOMES: Evaluating the clinical impact of PCSK9 inhibitor therapy over time

ODYSSEY OUTCOMES demonstrated that attainment of very low LDL cholesterol levels in acute coronary syndrome (ACS) patients reduces first cardiovascular events. But, given that ACS patients are at high risk of recurrent events, what is the impact of this treatment on the longer-term total cardiovascular burden?

In a new analysis of this trial, alirocumab treatment avoided twice as many nonfatal cardiovascular events or deaths compared with first events. These findings have important implications when weighing the societal costs of add-on PCSK9 inhibition in very high-risk patients.

John Chapman

PCSK9 Forum Editor Professor John Chapman (INSERM and University of Pierre and Marie Curie-Sorbonne, Paris, France) discusses implications of this analysis

Read the report here »

Dr Michael Szarek (SUNY Downstate School of Public Health, New York, USA, and a member of the Executive Steering Committee of the ODYSSEY Outcomes Trial) discusses this analysis.
AHA 2018 ODYSSEY OUTCOMES Total Events Analysis AHA 18 ODYSSEY OUTCOMES Take Home Messages from Total Events Analysis
Rationale, methods and key results Take home messages for clinicians

Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition coming soon.
New eBook
Questions & Answers

Why are new treatments needed?

Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2018. Please click here to unsubscribe from future mailings.